

6000+ articles screened via pub med, ASH, and Cochrane library using “Follicular lymphoma”, “R-CVP”, “Rituximab”, and “R-CHOP”

6 articles and 1 abstract from published and unpublished data were reviewed and screened as potentially relevant

1 ASH abstract and 1 prospective trial were excluded: Neither study differentiated efficacy of R-CHOP vs. R-CVP when compared to other treatment protocols for FL

1 prospective trial evaluating treatment efficacy with R-CHOP and R-CVP was excluded: It failed to separate results based on both treatment arms

4 studies were included:

- A) 2 were prospective studies comparing CHOP or CVP with and without Rituximab in the frontline treatment of FL
- B) 1 prospective trial evaluating responses to treatment with R-CHOP in patients with FL previously treated and untreated for the malignancy
- C) 1 prospective trial evaluating responses to treatment with R-CHOP in patients with FL who have relapsed from previous treatments